Scientific Content

Drug Discovery Dialogues

Dive into the latest from our binge-worthy series

We’re delighted to be partnering with thought leaders such as AZo Network & SelectScience as well as industry leaders to bring you the latest discoveries on our social media platforms and in our newsletters!

We’re sharing expert insights to advance breakthroughs in Drug Discovery with exclusive interviews and cutting-edge news from the community.  

Dive into the latest breakthroughs and get insights from industry leaders. 
Exclusive articles & videos from our partners.  

The Potential of Nanotechnology in Medicine: Insights from Prof. Ijeoma Uchegbu

Discover the future of medicine with Prof. Ijeoma Uchegbu, Chair in Pharmaceutical Nanoscience at University College London and President-elect of Wolfson College, Cambridge. Learn about her groundbreaking research focused on why medicines work for some but not others, and how improving drug delivery can enhance efficacy and reduce side effects. Explore how Ijeoma’s team uses nanoparticles, 1/100th the width of a human hair, to improve drug delivery and alternative routes of administration.

Read More
Drug Discovery Dialogues. Article. Maria Ramos Zapatero Insights on Patient-Derived Organoids. Interviewed by Alicia Overall

Maria Ramos Zapatero Insights on Patient-Derived Organoids

Maria Ramos Zapatero, a postdoctoral fellow at the Bodenmiller Lab at ETH Zurich, who presented her work on stromal regulation of patient-derived organoid drug responses at ELRIG’s Drug Discovery 2023. Alicia Overall delves into Maria’s career. Exploring her research journey, from her PhD to her current postdoctoral position, and her thoughts on the future of science, including the importance of collaboration and data analysis.

Read More
Text reads: Drug Discovery Dialogues. Article. Zahra Jawad's Journey to Becoming a CEO and Founding Creasallis. interviewed by Alicia Overall, Domainex

Zahra Jawad’s Journey to Becoming a CEO and Founding Creasallis

Zahra Jawad is the founder and CEO of Creasallis, a company focused on antibody remodeling to improve penetration and treatment of solid tumours. Zahra introduced the company and their revolutionary work in her talk, ‘Creating enhanced biotherapeutics for oncology: The drug discovery perspective’, at ELRIG Drug Discovery Liverpool 2023. Alicia Overall sat down with Zahra and discussed her time at Drug Discovery 2023, career, work, advice, and everything in between.

Read More

How does your genetics affect your weight and can drugs help?

Are the new class of GLP1 anti-obesity medications a panacea?

GLP1R agonists, including semaglutide (Ozempic) and tirzepatide (Mounjaro) are hugely effective in the treatment of obesity. Originally developed for Type 2 diabetes, these drugs also cause dramatic weight loss. But how do they work, and are these therapeutics the long sought after solution to obesity? Here I will explore the history of these drugs, explain their mechanisms of action, and discuss their importance as a therapeutic for obesity, type 2 diabetes, and heart disease, and crucially, whether or not they are safe in the long term.

Read More

Biophysical sensors in studies on pharmacologically-dark G protein-coupled receptors

Pawel will discuss the latest developments that have enabled us to obtain deeper insights into ligand-receptor interactions, receptor conformational changes, receptor-transducer interaction and receptor-mediated signaling of class F GPCRs. These methodologies and knowledge are fundamental to enlarge pharmacological toolbox for these proteins as well could be applicable to other understudied receptors e.g. orphan GPCRs.

Read More

Interested in becoming an

Exhibitor or Sponsor?

Although all ELRIG events are free of charge, we rely on our
valued exhibitors and sponsors to help fund our future events.